Kleresca® has been certified to be compliant with the standard and regulatory requirements for the medical device markets of Australia and Canada.
| BALLERUP, Denmark, Dec. 19, 2018 /PRNewswire/ -- Kleresca®, a medical technology company focused on the development and commercialisation of a unique biophotonic technology in dermatology, has been certified according to The Medical Device Single Audit Program (MDSAP). Audited by the National Standards Authority of Ireland (NSAI), Kleresca® has been certified to be compliant with the standard and regulatory requirements for the medical device markets of Australia and Canada. With minor additional audits and approvals, the certification will also apply to Brazil, Japan and the United States. The MDSAP certification is an add on to the quality management standard ISO 13485 that the company obtained in July 2018. The certification is an important stepping stone in Kleresca®'s expansion strategy and paves the way for entering new markets going forward. “We are excited to have secured the MDSAP certification as it gears the company for further expansion into key markets. It is essential to have the basics in place and take the right steps at the right time. So during 2019, we will focus on investigating our operational options for entering the US market,” says General Manager Mikkel Schoedt. As the FDA (US Food and Drug Administration) is part of the MDSAP programme, the audit report will be available to the administration on demand. However, an additional audit approval will possibly be required to enter the US market when Kleresca® is ready to expand further to the West. Currently, Kleresca® is developing markets in 10 countries including Italy, Spain, UK, Germany, France, Switzerland, Denmark, Norway, Belgium and Australia. The company portfolio includes four products: Kleresca® Acne Treatment, Kleresca® Skin Rejuvenation, Kleresca® Rosacea Treatment and Kleresca® Pre-Post. All products are based on an innovative technology that uses fluorescent light energy (FLE) to stimulate the skin’s biological processes. Visit http://news.cision.com/kleresca/ and www.fb-dermatology.com to learn more about Kleresca®. CONTACT: Nadia Vega Vasiljev This information was brought to you by Cision http://news.cision.com http://news.cision.com/kleresca/r/kleresca--achieves-mdsap-certification,c2703520 The following files are available for download:
SOURCE Kleresca |
View original content:
